With the advent of KIT‐targeted tyrosine kinase inhibitors (TKIs), the use of drugs like cladribine has declined. The multikinase inhibitor midostaurin is in widespread use for patients with advanced SM. The gene discussed is KIT; the disease is systemic mastocytosis.